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Abstract—By its very nature, rupture of the atherosclerotic plaque is difficult to study directly in humans. A good animal
model would help us not only to understand how rupture occurs but also to design and test treatments to prevent it from
happening. However, several difficulties surround existing models of plaque rupture, including the need for radical
interventions to produce the rupture, lack of direct evidence of rupture per se, and absence of convincing evidence of
platelet- and fibrin-rich thrombus at the rupture site. At the present time, attention should therefore focus on the
processes of plaque breakdown and thrombus formation in humans, whereas the use of animal models should probably
be reserved for studying the function of particular genes and for investigating isolated features of plaques, such as the
relationship between cap thickness and plaque stability. (Arterioscler Thromb Vasc Biol. 2003;23:535-542.)
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Most of the middle-aged and elderly population in thedeveloped world and in many parts of the developing
world have atherosclerosis, and about a quarter will die of it.
Much has been achieved by conventional measures to prevent
the development of atherosclerosis, but the outcome of
persons suffering a coronary occlusion has not changed that
much over the years. Nearly half of all people who develop a
first acute myocardial infarction will be dead within a month.
For this reason we urgently need to understand what leads to
the fatal event and to identify and test treatments that prevent
it from occurring. Up to quite recently, it was assumed that
the risk of death was directly related to the burden of disease:
the greater the extent of atherosclerosis, the higher the risk.
About 10 years ago, a paradigm shift occurred when it was
realized that the fatal complications of atherosclerosis, myo-
cardial infarction, and stroke do not necessarily occur in those
with the heaviest burden of disease. Rather, acute blockage of
an artery in the brain or heart is often caused by a clot that
occurs at the site of rupture of a so-called “vulnerable
plaque.” Such vulnerable plaques consist of a lipid-rich
thrombogenic core that is separated from the arterial blood-
stream only by a slender and fragile layer of tissue, the
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fibrous cap. These lesions need not be large, nor need they be
particularly old. No longer is the final event seen as “the
straw that breaks the camel’s back,” the last link in an
inexorable process taking place over a very long time, but as
a catastrophe resulting from an acute imbalance of stabilizing
and destabilizing forces within the lesion. Such ruptures recur
over many years but do not cause usually complete occlusion
of the vessel, resulting instead in mural thrombi that are
incorporated into the plaque. As a result, rupture of the
coronary vasculature is often clinically silent. In addition,
thrombosis may occur at the site of an eroded atherosclerotic
plaque even without a tear in the fibrous cap of the lesion.1
The search for an animal model of atherosclerotic plaque
rupture should be seen against this background. Also, it
should be remembered that it has never been easy to find a
good animal model of the atherosclerotic process per se.
Atherosclerosis is a disease that really only affects humans
and 1 or 2 other species, such as the pig and certain primates,
with the result that researchers have had to resort to geneti-
cally modified models to even partially reproduce the
condition.
Several reviews dealing with plaque instability in animal
models have been published within the last few years,2–5
including 1 in this journal.6 The Macrophage Function and
Stability of the Atherosclerotic Plaque (MAFAPS) consor-
tium was established as part of the Fifth Framework Program
of the European Union with the aim of better understanding
the role of the macrophage in plaque stability.7
In the present work, the members of the MAFAPS consor-
tium will not attempt to duplicate these reviews, but rather, in
the light of their own research experience, describe their
particular view of the current state of play in the search for a
viable animal model of plaque stability. The MAFAPS
consortium will also give its impression of the direction in
which research in this area might proceed in the future.
Why Do We Need a Good Animal Model of
Plaque Rupture?
By its very nature, rupture of the atherosclerotic plaque is
difficult to study in humans. If at all, its presence in the living
person can be divined only indirectly by means of angiogra-
phy or by newer techniques, such as fast multi-slice comput-
erized tomography. Because rupture of the atherosclerotic
plaque occurs in a stochastic fashion, it is also exceedingly
difficult to identify trigger factors and equally hard to
investigate treatments that directly stabilize the plaque.
A good animal model would help us not only to understand
how rupture occurs but also to design and test treatments to
prevent it from happening. In addition, animal models gen-
erally have the advantage of a shorter time to lesion devel-
opment and allow the investigation of pathology in a large
number of individuals.
Importance of Plaque Rupture in Humans
Plaque Rupture and Thrombosis
As recently pointed out elsewhere,1 in 1858 the incomparable
Rudolf Virchow noted that the term “atheroma” is borrowed
from the description of a dermal cyst, that is, a fatty
pultaceous mass (“Grützbalg”) enclosed within a fibrous
capsule.8 The current paradigm of plaque rupture suggests
that this capsule can rupture, exposing the thrombogenic core,
analogous to the bursting of a cyst or abscess. This interpre-
tation is based both on autopsy1,9–11and angiographic12,13
studies. This model has undoubtedly been of great use in
conceptualizing the pathophysiology of myocardial infarction
in particular. However, the charm of its compelling imagery
should not blind us to important contradictions that exist
within it. These have been outlined in recent excellent
reviews by Virmani1 et al and Badimon3 and are summarized
in Table 1.
Based on current research, therefore, 2 things are clear.
First, thrombotic occlusion of a coronary artery may occur
without rupture of an atherosclerotic plaque. Second, rupture
of an atherosclerotic plaque within a coronary artery does not
usually lead to thrombotic occlusion of that artery.
What Are the Factors Governing Plaque Stability?
Despite the absence of a clear-cut link between plaque
rupture and occlusive thrombosis, there is no doubt that a
defect in the surface of the atherosclerotic plaque is almost
always associated with mural thrombosis, which at the least
leads to a growth of the atherosclerotic plaque. It is therefore
important to examine the current state of knowledge on
factors regulating plaque stability. This information will be
important later when we come to consider the applicability of
currently available animal models.
The atherosclerotic plaque is not a static structure. Rather,
its status at any given moment is the result of the complex and
dynamic interplay of a very large number of cellular and
humoral factors. Here, we will confine ourselves to the
factors thought to affect the stability of the fibrous cap, the
distinct layer of connective tissue overlying the lipid core of
the vulnerable lesion.1
The acellular component of the fibrous cap consists largely
of filamentous type I collagen and proteoglycans. However,
other forms of collagen, such as reticular type VIII collagen,
are also present, particularly in the so-called shoulder regions
where the cap joins the remainder of the arterial wall. These
TABLE 1. Contradictions That Exist Within the Existing
Paradigm of Plaque Rupture
1. Autopsies have shown that a substantial minority of victims of sudden
coronary death show superficial plaque erosion without plaque
rupture.15,87–90
2. In more than 200 cases of sudden coronary death, only one third of all
lesions showed signs of plaque rupture. Even among those lesions with
thrombi, only about two thirds showed rupture. Many of the thrombotic
nonruptured lesions did not even show infiltration of macrophages and
lymphocytes as signs of inflammation, displaying instead abundant
smooth muscle cells in a proteoglycan-rich matrix.9,11,15,91
3. Although plaque disruption accounts for up to two thirds of patients in
whom unstable angina or acute myocardial infarction develops, in most
cases plaque disruptions are asymptomatic, although they may contribute
to the growth of the atherosclerotic plaque.3
4. In addition to rupture or erosion of an atherosclerotic plaque, the
occurrence, composition and size of a thrombus are regulated by
mechanical hemodynamic effects, the thrombogenicity of the arterial
surface, the relative concentration of cellular blood components, and the
efficiency of fibrinolysis.3
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are the regions where fissures and tears are most likely to
occur. The fibrous cap is said by some authorities to be “thin”
when it is less than 65 m in thickness.1
The cellular composition of the fibrous cap may vary
considerably. It may be rich in inflammatory cells, chiefly T
lymphocytes and macrophages, and may contain many
smooth muscle cells, or it may contain almost no cells at all.
Erosion of the fibrous cap is said to be present when
endothelium is absent and the exposed intima consists mainly
of smooth muscle cells and proteoglycans. Typically, eroded
fibrous caps do not show marked signs of inflammation.14,15
What Causes Atherosclerotic Plaques to Rupture?
The reasons for thinning and rupture of the fibrous cap are not
known. Two main hypotheses have been proposed. The first
is that rupture is a result of loss of smooth muscle cells,
thought to be the main producers of cap-stabilizing collagen.
This is caused by the loss of cells from apoptosis. Bennett and
others16,17 have suggested that such apoptosis may be medi-
ated by the interaction between smooth muscle cells and
monocyte/macrophages. Apoptosis of smooth muscle cells
has also been shown to be promoted by chymase produced by
mast cells, which are present in the plaque in significant
numbers.18–21 It may even be the case that smooth muscle
cells in the atherosclerotic plaque undergo apoptosis by
default unless their viability is maintained, for example, by
the presence of insulin-like growth factor 1 in the interstitial
milieu.22 In addition to undergoing apoptosis, smooth muscle
cells within the plaque are very slow to divide23–25 and stop
proliferating altogether after 2 to 5 passages.26
The second hypothesis is that plaque rupture is the result of
an imbalance between the production of plaque-stabilizing
collagen on the one hand and the action of corrosive enzymes
on the other. These enzymes are present in the form of
metalloproteinases, which derive mainly from macrophages27
and cathepsins, which are produced by smooth muscle
cells.28,29 There is much experimental evidence for the pres-
ence of active metalloproteinases, chiefly matrix metallopro-
teinases 1 and 9, within the atherosclerotic plaque.30–32
However, it is not entirely clear how these metalloproteinases
are regulated. Tissue inhibitors of metalloproteinase activity
are widespread within the lesion.33 Moreover, macrophages
have been shown not only to produce collagen-degrading
enzymes but themselves to be a source of collagen.34 Finally,
mast cells are sources not only of degrading enzymes,35,36 but
also, like macrophages, of collagen.37
Animal Models of Atherogenesis and
Plaque Rupture
Much has been achieved with the use of animal models,
particularly in unraveling the function of particular genes.
Animal models have been of less use, however, in under-
standing the pathophysiology of human disease. From the
foregoing, it is clear that plaque rupture in humans and, more
importantly, the thrombotic occlusion of the artery that
sometimes accompanies it, are the final events in a long and
complex pathophysiological process that is not completely
reproduced in any other animal. In assessing animal models
of plaque rupture, it is therefore useful first to consider what
would be the ideal features of such a model (Table 2).
It is clear that it will be very difficult if not impossible to
find an animal model that exhibits all of the features shown in
Table 2. Nevertheless, it is sobering to reflect on how few of
these features are exhibited by most of the existing models.
Over the years, many animal models of atherosclerosis have
been developed. In latter years, models of plaque rupture
have also begun to emerge. Each of these models has specific
advantages and disadvantages, as will be described in the
following sections.
Nonmouse Animal Models of Atherogenesis
Rabbits develop lipid-rich arterial lesions with some of the
features of atherosclerosis only if they are fed large amounts
of cholesterol and fat—components that are usually lacking
in their vegetarian diet. Indeed, it was in cholesterol-fed
rabbits that aortic cholesterol accumulation was first noted by
Anitschkow in St. Petersburg 90 years ago.38 Such diets result
in cholesterol levels many times greater than those seen in
humans. The lesions that rabbits develop bear only a super-
ficial resemblance to human atheroma, being more fatty and
macrophage rich.3
White Carneau pigeons develop lesions that are morpho-
logically and ultrastructurally more similar to human athero-
sclerosis.39–42 However, in contrast with humans, suscepti-
bility to atherosclerosis in these birds lies entirely at the level
of the arterial wall. Cholesterol levels are normal and other
risk factors are absent,39 with the lesions in the pigeons
thought to be entirely the result of an inherited43 defect in
cholesterol efflux from macrophages.44,45
On a high-cholesterol diet, primates, including chimpan-
zees, squirrel monkeys, howler monkeys, rhesus monkeys,
and cynomolgus monkeys, develop a form of atherosclerosis
that is very similar to that of humans.46–49 However, the cost
of primates is prohibitive, and many of these species are
protected. Thus, work on atherosclerosis in primates is today
generally confined to the study of complex issues, such as the
effects of psychological stress.50
TABLE 2. A Proposed List of Ideal Features of an Animal
Model of Plaque Rupture
1. The atherosclerotic process in the animal model should be histologically
identical to that in humans.
2. The atherosclerotic plaque in the animal model should show the same
vulnerability to rupture as its human counterpart.
3. The events leading to vulnerability and rupture: cap/core ratio, cellular
composition, collagen production and breakdown, should as far as
possible be identical to those in humans.
4. Plaque rupture in the animal model should occur without the need for
manipulations such as cuffing of the artery or insertion of balloon
catheters.
5. Plaque rupture should at least in some cases be accompanied by the
formation of platelet-rich fibrin thrombi.
6. Response to treatment in the animal model should have the potential for
duplication in humans.
7. The species should be available for research and easy and economical to
maintain, and plaque rupture should occur under reproducible conditions
within a reasonable time frame.
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The pig is one of the most useful currently available animal
models of atherosclerosis. In time, pigs develop atheroscle-
rosis even on a normal porcine diet.51–55 When fed cholester-
ol, they develop plasma cholesterol levels and atherosclerotic
lesions that are similar to those seen in humans. The white
Belgian pig variety also exhibits sudden coronary death when
under stress.3 However, maintenance of pigs is expensive and
difficult, requiring special facilities that are beyond the
capabilities of most laboratories.
Dogs and rats are generally very resistant to atherosclerosis
and only develop it when their diets are extensively modi-
fied.3 In recent years, however, some transgenic rat models
have been produced that develop lesions resembling
atherosclerosis.56–59
Of Mice and Men, or Why Small Is Not Always Beautiful
Because of ease in handling, the wide knowledge base
concerning mouse physiology, and the large amount of mouse
genetic information available, most researchers in recent
years have focused on mouse models for the study of
atherosclerosis.60–70
Before proceeding to a description of the individual mod-
els, it is important first to recall the fundamental limitations of
the mouse model. Mice do not develop atherosclerosis
without genetic manipulation. They have a lipid physiology
that is radically different from that in humans, most of the
cholesterol being transported in HDL-like particles. Further-
more, mice weigh about 25 g, some 3000 times less than the
average human. Because mouse cells are about the same size
as human cells, this means that a section of coronary artery in
the mouse contains about 3000 times fewer cells than an
equivalent section of human coronary artery. This is reflected
in the histology of mouse arteries, in which the endothelial
layer lies directly on the internal elastic lamina and the media
consists of only a few layers of smooth muscle cells. In
contrast with their counterparts in humans, atherosclerotic
lesions in the mouse coronary artery often extend beyond the
elastic lamina.64 Remodeling of the media and aneurysms are
also common in mice.71–74 Furthermore, it is difficult in mice
to make a distinction between plaque erosion, as defined by
endothelial denudation, and complete rupture of the fibrous
cap.64 Although classic eccentric atheromas with a single
fibrous cap exist in lesion-prone mouse models, multiple
necrotic core areas with or without separate fibrous caps are
the norm.66,75,76 As pointed out by Calara and colleagues,64
disruption of these lesions may not mimic plaque rupture in
humans, placing a fundamental limit on the applicability of
mouse models for investigation of rupture mechanisms.
In addition to these difficulties arising from the differences
between mouse and human biology, there are important
issues that need to be remembered in interpreting the results
obtained in mouse models that have been derived by genetic
manipulation. Problems may, for example, occur when 2
different genetic models of a particular illness are used to
investigate the effect of a third genetic manipulation. An
important example in the field of atherosclerosis research
concerns studies investigating knocking out the gene for the
type A scavenger receptor in different genetic models of
atherosclerosis. Suzuki and colleagues77 reported that delet-
ing this scavenger receptor in apoE knockout mice reduced
atherosclerotic lesion size by 60%. However, de Winther et
al78 found that in the apoE3 Leiden mouse model of athero-
sclerosis, inactivation of the scavenger receptor actually
increases lesion size. A possible explanation for this differ-
ence relates to the role of apoE in the vessel wall. ApoE has
been shown to mediate efflux of cholesterol from macro-
phages, and it is therefore possible that deficiency in apoE
predisposes to macrophage foam cell formation. This process
of foam cell formation might be expected to be inhibited by
deletion of the scavenger receptor, the main route by which
cholesterol loading of macrophages occurs. By contrast,
macrophages from mice bearing the apoE3 Leiden gene show
normal apoE-mediated cholesterol efflux, so that scavenger
receptor-mediated cholesterol uptake does not lead to en-
hanced foam cell formation, allowing other presumably
antiatherogenic functions of the scavenger receptor to come
to the fore.
As indicated by Sigmund,79 a second major problem is the
genetic heterogeneity that exists among the strains used to
generate transgenic and knockout mice. This may lead to a
situation where animals containing exactly the same genetic
manipulation exhibit profoundly different phenotypes when
present on diverse genetic backgrounds. For example, the
extent of atherosclerosis among apoE knockout mice on a
standard atherosclerosis-prone C57BL/6 background was
found to be 7 times greater than apoE knockout mice with an
atherosclerosis-resistant FVB genetic background.80 The
ideal solution to this problem is to use inbred isogenic strains
in which the experimental and control mice differ only at the
target locus. The next best alternative is to develop a program
of inbreeding to a common, congenic strain, that is, one that
is genetically identical to the control strain except for the
single region of the chromosome containing the target gene.
This is time-consuming and expensive. Six generations, or 2
years, of backcross breeding are required before the genetic
backgrounds are more than 99% homogenous, with rapidly
diminishing returns thereafter. For example, 4 more genera-
tions are needed to increase genetic homogeneity from 99.2%
to 99.9%.79 These problems make it imperative that a detailed
description of the genetic background of all mouse models
used in transgenic experiments be published, and that the
genetic background should always be taken into account
when assessing experimental results.
Animal Models of Plaque Instability and Rupture
Despite the drawbacks mentioned above, several models have
been reported recently that plausibly reproduce many of the
salient features of plaque ruptures in humans. The only
nonmouse model of plaque rupture was presented by Rekhter
et al in 1998.81 The aim of this model was not to investigate
the pathophysiological mechanisms underlying the develop-
ment of the vulnerable lesion but rather to design a model “to
evaluate plaque mechanical strength/vulnerability character-
istics.” In this model, 2 balloon catheters were used to
mechanically injure and thus produce a lesion in the thoracic
aorta of a cholesterol- and fat-fed rabbit. A third indwelling
balloon catheter was then inflated and deflated to produce
rupture of the lesion. From this description, it is clear that this
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animal model may be suitable for measuring the mechanical
strength of a plaque and, perhaps, for investigating throm-
botic sequelae, but cannot be expected to provide much
information about the pathophysiology of plaque rupture in
humans.
The first indirect evidence of plaque rupture in the apoE
knockout mouse model of atherosclerosis appeared in 1998,
when Reddick et al82 reported thrombus formation in the
aortas of mice that were injured by squeezing with a forceps.
This rather unphysiological model was followed up by a
report by Rosenfeld et al65 that elderly apoE knockout mice
(60 weeks old) develop lesions in the brachiocephalic artery
that are characterized by the presence of collagen-rich fibro-
fatty nodules and xanthomas. These nodules contained ne-
crotic cores and displayed evidence of intramural bleeding.
This bleeding was interpreted as possibly being due to plaque
rupture. Moreover, from 42 weeks onward, mice exhibited
layered lesions, implying, the authors suggested, multiple
events. In a more recent report, Rosenfeld’s group reported
that in 30-week-old apoE-deficient mice, administration of a
large dose of simvastatin (50 mg/kg/day) reduced the fre-
quency of bleeding and calcification within lesions in the
brachiocephalic artery, which was interpreted as evidence for
“stabilizing effects [of simvastatin] on advanced atheroscle-
rotic lesions.”83 Calara and colleagues64 followed 82 choles-
terol-fed apoE and LDL receptor knockout mice for up to 12
months and 33 chow-fed apoE knockout mice for up to 20
months. Of the 82 cholesterol-fed animals, 3 showed aortic
plaque rupture and/or thrombi, whereas of the 33 chow-fed
mice, 18 showed atherosclerosis of the coronary arteries. In 3
of these 18 animals, blood-filled channels were seen within
the coronary lesions. This was taken to indicate the presence
of previous plaque disruption and thrombosis, followed by
recanalization. These 3 mice also showed deep ruptures and
thrombosis of the aortic origin.
Finally, much interest was generated by 2 recently reported
models of plaque rupture in apoE knockout mice. In the first
of these, from Bristol in the United Kingdom, apoE knockout
mice with an unusual mixed C57BL6/129SvJ genetic back-
ground were fed a diet containing 21% lard and 0.15%
cholesterol for up to 14 months.62,63 Most of these mice
developed atherosclerotic plaque rupture associated with
luminal thrombus at the point where the brachiocephalic
artery branches into the right common carotid artery. The
ruptures were characterized by fragmentation and loss of
elastin and smooth muscle cells in the fibrous caps of
relatively small and lipid-rich plaques overlying large com-
plex lesions. Of 98 such mice, 51 had an acutely ruptured
plaque in the brachiocephalic artery and 64 died suddenly.
However, the incidence of sudden death did not differ
between those with brachiocephalic rupture and those with-
out. An undisclosed number of mice in this study also
suffered myocardial infarction. In the second study, lesions
were induced in apoE knockout mice by placement of a
silastic collar around the carotid artery.70 The resultant
plaques were then incubated transluminally with adenovirus
bearing a p53 transgene. Overexpression of p53, a tumor
suppressor gene that promotes apoptosis, reduced the cellular
and extracellular content of the cap of the lesion, with a
reduced cap/intima ratio. When these mice were made hyper-
tensive by treatment with phenylephrine, 40% developed
rupture of the p53-treated plaques. Several articles have also
appeared in recent years of myocardial infarction in apoE
knockout mice without definite evidence of plaque rup-
ture.68,69,84 For the sake of brevity, therefore, these models
will not be discussed further here, even though some have
enthused that their existence should “finally put to rest the
notion that mice cannot be models of plaque rupture.”85
Usefulness of Current Animal Models of Plaque
Instability and Rupture
Of the models of plaque rupture presented thus far, none can
be regarded as ideal. Both the rabbit model presented by
Rekhter et al81 and the apoE knockout mouse p53/silastic cuff
model70 required such heroic measures to produce evidence
of plaque rupture that they can tell us little about the
pathophysiology of this condition. The usefulness of these
models is thus more or less confined to studies of the
mechanical process of rupture itself. More interesting from
the etiological and therapeutic points of view are the apoE
mouse models in which plaque rupture was seen in elderly
fat- and cholesterol-fed mice.62–65 However, these models too
are surrounded by caveats. In the report of Calara et al,64
evidence of rupture was indirect and was seen much less
frequently (about 5% of the animals) than occurs in human
atherosclerosis. In the Rosenfeld et al65 model, evidence of
rupture was also indirect and was seen in the brachiocephalic
artery in particular. Finally, in the Bristol model,62,63 plaque
rupture was again focused on the brachiocephalic artery, and
was seen only in older mice after prolonged feeding with a
very high-fat diet. The Bristol group have speculated that the
predilection for plaque rupture in the brachiocephalic artery
may reflect the high degree of tension in the wall of this artery
in the mouse. A more general drawback of both the Rosenfeld
and Bristol models is that neither shows convincing evidence
of the formation of platelet and fibrin-rich thrombus at the site
of presumed rupture. This is a very important limitation
because infarction of the heart or brain in humans is not
caused by rupture of the artery per se, but by the formation of
an occlusive blood clot that is rich in platelets and fibrin.
Perhaps as a reflection of this lack of thrombosis, death of the
mice in Bristol was not related to plaque rupture. Further-
more, in the absence of thrombosis, intraplaque hemorrhage
in these models has been presumed to reflect prior plaque
rupture, but this is not necessarily the case.5 The Rosenfeld
and Bristol models also have the disadvantages of the
expense required to maintain the mice for more than a year
and the variable incidence of plaque rupture.
Conclusions, Directions for the Future
Atherosclerosis in humans is a multifactorial condition that
develops over many years, and modeling it in animals is a
notoriously tricky business. Reproducing the events leading
up to occlusive thrombosis, the event that actually kills and
disables humans, is even more challenging. In humans,
thrombosis and plaque rupture are linked, yet either one can
occur without the other. We still do not know why an
occlusive clot occurs at a particular location at a particular
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time, but it is certain that this is only the last act in a complex
drama, which, like some modern theater, is likely to contain
the occasional random event. In view of these deficiencies,
can animal models be regarded as a help? The answer is a
qualified maybe. Existing models are useful for exploring
certain features of the pathogenesis of atherosclerosis, partic-
ularly in relation to unraveling the function of particular
genes. They are also useful for investigating isolated features
of plaques such as the relationship between cap thickness and
mechanical stability. However, they are less helpful in mod-
eling the complications of atherosclerosis, such as rupture and
thrombosis. Because of the complexity of the processes
involved, it is not certain that a good model of these
complications will ever be found, particularly when the
narrow species specificity of atherosclerosis is taken into
account. This is also true of studies of potential treatments
intended to stabilize the plaque, any results of such studies
obtained in animals must be regarded as strictly preliminary
and require verification in humans.
Directions for the Future
In studies of plaque rupture, despite the difficulties involved,
more attention should be paid to the study of the processes of
plaque breakdown and thrombosis formation in humans
themselves. A good example of such work is a recent
investigation of Faber et al,86 who used a subtractive hybrid-
ization technique to identify genes that are differentially
regulated in human atherosclerotic lesions that showed evi-
dence of plaque rupture. The currently available animal
models seem unlikely to play more than a supporting role in
this research.
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